Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Nierenberg

Psychiatry Boston, MA Medical Doctor

NPI 1336113661 CMS profile 287427

50 Staniford St, Suite 580, Boston, MA 02114

Open in the dashboard

General payments

$93,713

100 records reported · program years 2019–2025

Research payments

$6,201

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,508 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Andrew Nierenberg of Boston, MA is reported in the CMS Open Payments database as having received $93,713 across 100 general payments and $6,201 in research payments paid to them. Separately, studies naming them as principal investigator received $13,508 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,856 12
2024 General $13,058 20
2023 General $15,207 12
2022 General $13,373 3
2021 General $4,340 5
2020 General $9,567 8
2020 Research $6,201 2
2019 General $26,312 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Nierenberg
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Andrew Nierenberg were reported at $11,856. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Andrew Nierenberg Psychiatry median Middle half National median
2019 $26,312 $184 $59–$605 $163
2020 $9,567 $119 $36–$372 $114
2021 $4,340 $143 $43–$576 $132
2022 $13,373 $153 $50–$590 $149
2023 $15,207 $170 $56–$651 $160
2024 $13,058 $179 $57–$673 $164
2025 $11,856 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Research & Development, LLC $20,475 5 payments
  2. Merck Sharp & Dohme Corporation $15,143 16 payments
  3. Sage Therapeutics, Inc. $11,336 14 payments
  4. ACADIA Pharmaceuticals Inc $10,220 15 payments
  5. E.R. Squibb & Sons, L.L.C. $10,056 11 payments
  6. Abbott Laboratories $7,448 14 payments
  7. Eisai Inc. $5,476 9 payments
  8. Alkermes, Inc. $4,500 2 payments
  9. Jazz Pharmaceuticals Inc. $3,938 9 payments
  10. Sunovion Pharmaceuticals Inc. $2,909 3 payments
  11. Other $2,213 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $77,017 27 payments
  2. Travel and Lodging $11,040 34 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  4. Honoraria $1,800 1 payment
  5. Food and Beverage $1,357 37 payments
Products named General payments · program years 2019–2025
  1. NUPLAZID $10,220 15 payments
  2. INFINITY $6,527 11 payments
  3. SUNOSI $3,938 9 payments
  4. LATUDA $2,909 3 payments
  5. Qelbree $1,800 1 payment
  6. PROCLAIM $921 3 payments
  7. ABILIFY MYCITE $413 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Neuronetics, Inc. $6,201 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

185

Median for Psychiatry: 574

Drug cost

$33,344

Median for Psychiatry: $27,624

Branded share of claims

20%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Aripiprazole Brand 12 $19,844
Lunesta Eszopiclone Brand 12 $10,514
Quetiapine Fumarate Er Quetiapine Fumarate Brand 13 $836
Quetiapine Fumarate Generic 25 $531
Olanzapine Generic 11 $364
Lamotrigine Generic 15 $282
Armodafinil Generic 11 $239
Lorazepam Generic 28 $214
Lithium Carbonate Generic 13 $175
Trazodone Hcl Generic 15 $162

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$5,595

Medicare's payments for the services billed

Medicare patients

15

Average age 70

Services billed

86

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record